-
Posted by
Two Blokes Jul 22 -
Filed in
Stock
-
8 views
hVIVO PLC (AIM:HVO), the London-listed clinical research group, said it is trading in line with previous market expectations, as it told investors its acquisition strategy is bearing fruit. The group, which recently bought new businesses of CRS and Cryostore, posted revenues of £24.2 million for the six months to the end of June, down from £35.6 million a year earlier, but in line with forecasts for the year of £47 million.
